Micro Labs gets CDSCO Panel Nod to manufacture and market Lifitegrast 5% eye drops
New Delhi: Micro Labs has got a green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to manufacture and market Lifitegrast 5% eye drops with the condition that the drug should be sold by retail under the prescription of Ophthalmologist only.
This came after the firm presented Phase-III clinical trial report before the committee.
Lifitegrast is in a class of medications called lymphocyte function-associated antigen-1 (LFA-1) antagonist. Lifitegrast works by reducing the swelling in the eye tissues.
Lifitegrast ophthalmic solution 5% is labeled for the treatment of dry eye disease, also known as keratoconjunctivitis sicca. It is an inhibitor of the lymphocyte function–associated antigen 1 (LFA-1) and has been shown to reduce immune-mediated inflammation.
Also Read:Glenmark Gets CDSCO panel nod for Phase IV CT of COPD drug
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.